Editorial
941 Treatment of rheumatoid arthritis: strategies for achieving optimal outcomes
A Ciberefy, Y Yacza

943 Annals of the Rheumatic Diseases: an update
T K Kent

Viewpoint
945 Cytokines in Sjögren’s syndrome: potential therapeutic targets
N Reiszech, P F Tate, G G Illi

Review 2010
949 Spondylarthropathy: state of the art and future perspectives
D van der Heijde, W P Maksymowych

955 Self-management of rheumatic diseases: state of the art and future perspectives
M D Iversen, A Hammond, N Betteridge

Recommendations
964 EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs

Clinical and epidemiological research
976 Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA
J L Nam, K L Winthrop, R F van Voolenhoven, K Pavelka, G Valesini, E M A Hansen, G Worthy, R Landewé, J S Smolen, P Emery, M W Bach

987 Current evidence for a strategic approach to the management of rheumatoid arthritis with disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
R Kneve, M Schoels, T W J Haiswerga, D Altevetha, G R Barretta, B Come, BB Landewé, J S Smolen, T Sokka, M F M van der Heijde

995 Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
M Schoels, J Wong, D L Scott, A Zink, P Richards, R Landewe, J S Smolen, D Altevetha

1004 Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
C Caassaux-Viala, J S Smolen, R Landewé, M Dougados, T K Kent, E M Molá, M Scholle-Vosha, P van Riel, L Gosses

1010 Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis
S L Gómez, J W W Jacoba, M Canudo, J Gomez-Reino, M Koulomamas, J S Smolen, R Landewé

1015 Patient and rheumatologist perspectives on glucocorticoids: an exercise to improve the implementation of the European League Against Rheumatism (EULAR) recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases
Contents

Basic and translational research

1172 Oxidative damage in synovial tissue is associated with in vivo hypoxyonic status in the arthritic joint
M Brinca, A Kennedy, U Fearen, C T Ng, D J Veale, J N O’Sullivan

1179 Oral treatment with a Brachystelma calycinum D don plant extract reduces disease symptoms and the development of cartilage lesions in experimental dog osteoarthritis: inhibition of protease-activated receptor 2
C Belau, J Martel-Pelletier, J Ciron, F Paré, E Troncy, M Moreau, J-P Pellerin

1185 Synergistic induction of local glucocorticoid generation by inflammatory cytokines and glucocorticoids: implications for inflammation associated bone loss
K Kaur, R Handy, M M Ahasan, M Epjzen, J P van Leeuwen, A Filez, A M Thomas, K Raza, C D Buckley, P M Steward, E H Rabitt, M Hewson, M S Cooper

1191 A gain of function polymorphism in the interleukin 6 receptor influences RA susceptibility
I Manoueu, K Walters, J Winfield, D E Rae, A G Wilson

1195 Toll-like receptor 7 (TLR7) modulates anti-nucleosomal autoantibody isotype and renal complement deposition in mice exposed to syngeneic late apoptotic cells
Z-Y Fan, S Mayer, K Schwarz, J Azhll, S Akira, S Uematsu, A D Farris

1200 Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis
H M Baldwin, T Itc-Itara, J D Isaacs, C M U Hilkens

1208 Novel expression signatures identified by transcriptional analysis of separated leucocyte subsets in systemic lupus erythematosus and vasculitis
P A Lyons, E F McKinney, T F Rayner, A Hatton, H B Wolfenden, M Koulomakis, T C Freeman, D R W Jayne, A N Chaudhury, K G C Smith

1214 Synovial immunopathology in haemochromatosis arthropathy
G C Heldand, E Aigner, T Dallas, E Schindegovici, V Krenn, C Thaler, G Weiss, J H Dostler, C Datz, G Schett, J Zweima

1220 Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease
E Tourkina, M Richard, J Oates, A Hoffste, M Bonner, P Góz, R Visconti, J Zhang, S Zwyby, C M Hatfield, R M Silver, S Hoffman

1227 Serum branched-chain amino acid to histidine ratio: a novel metabolic biomarker of knee osteoarthritis
G Zhai, R Wang-Santle, D J Hart, N K Arden, A J Hakem, T Illg, T D Spector

1232 Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout
W Uretz, A Taniguchi, N Arzata, E Inoue, Y Kanat, M Yamaizaka, H Endou, N Kamatake, H Yamanaka

1235 Levels of plasmacytoid dendritic cells and type-2 myeloid dendritic cells are reduced in peripheral blood of patients with primary Sjögren’s syndrome
P Vogelsong, JG Braun, G Oğuzdelenken, K Skarstein, R Jonsson, S Appel

1239 Loss of imprinting of IGF2 characterises high IGF2 mRNA-expressing type of fibroblast-like synoviocytes in rheumatoid arthritis
A Martin-Triollo, J G I van Rietschoten, T C G Timmer, F M Rodriguez, T W J Huizinga, P P Tek, S Marsal, S M Ibralton, B A C Dijkmans, T C T M van der Pauw Kranen, C L Verwoer

1243 The chromosome 16q region associated with ankylosing spondylitis includes the candidate gene tumour necrosis factor receptor type 1-associated death domain (TRADD)
J J Fimton, D Harvey, T Kanade, L H Appleton, C Farfax, M A Stone, R D Suarez, J D Reveille, M H Weisman, M M Wadt, M A Brown, B P Wardworth

1247 Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus
K Kim, S-K Cho, A Sestak, B Namjou, C Kang, S-C Bai

Letters

1251 Tumour necrosis factor blockade mediates altered serotonin transporter availability in rheumatoid arthritis: a clinical, proof-of-concept study
J Cavanagh, C Patterson, J McLean, S Pimlett, M McDonald, J Patterson, D Wyper, I McInnes

1252 The SLC22A12 gene is associated with gout in Han Chinese and Solomon Islanders

1254 Successful use of rituximab in a patient with Churg–Strauss syndrome and refractory central nervous system involvement
J Saito, K Owczarszy, S Rösgen, H Peterit, M Hallek, A Rukbert-Roth

1255 Limited validity of the American College of Rheumatology criteria for classifying patients with gout in primary care
H J E M Janssens, M Janssen, E H van de Lisdonk, J Fransen, P L C M van Riel, C van Weel

Volume 69 Issue 6 | ARD June 2010